Navigation Links
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
Date:6/23/2008

an result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first in class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

P-LLY

Plavix(R)/Iscover(R) are registered trademarks of Sanofi-Synthelabo Inc.

This press release contains certain forward-looking statements about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the compound will receive regulatory approval, that the regulatory approval will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. GSK Update on FDA Review of Promacta(R) (Eltrombopag)
8. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
9. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
10. Got Fat?: Plastic Surgeons Review Fat-Melting and Fat-Grafting Procedures
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 Creekridge Capital, ... of its sales channels by adding two new sales ... as a Regional Sales Manager and Stefanie Stark ... Mr. Puma comes to Creekridge with over 20 ... his role at Creekridge, Mr. Puma will be responsible ...
(Date:6/3/2015)... 2015  The International Confederation of Midwives (ICM) has ... as a standard for midwives trained to ICM,s competency ... in consultation with ICM experts. Direct Relief will provide ... countries. As many as one in 30 ... or childbirth.  Skilled birth attendants such as midwives offer ...
(Date:6/3/2015)... 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... agreement with AbbVie (NYSE: ABBV ) to develop ... Halozyme,s ENHANZE ™ platform. ... receive an initial $23 million payment, followed by ... of up to nine collaboration targets. These payments ...
Breaking Medicine Technology:Creekridge Capital Strengthens Sales Team 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3
... Patient Record Sharing , and Secure ... Among Physicians , DAYTON, Ohio, Oct. 29 ... (HSI) announce an effort to create virtual teams that connect primary ... care of patients, improving the quality and safety of care while ...
... IRVINE, Calif., Oct. 29 PRO-DEX, INC. (Nasdaq: PDEX ... quarter ending September 30, 2009. In addition, Pro-Dex announced ... renewed, a new marketing director has been hired, a product ... shipments have been made of a newly developed product. , ...
Cached Medicine Technology:Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 2Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 3Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10
(Date:6/3/2015)... June 03, 2015 Visual BI ... solutions, today announced the launch of the second ... for SAP® BusinessObjects™ Design Studio. The Design Studio ... capabilities and advanced functionalities into their dashboarding projects. ... suite, Visual BI is adding key components for ...
(Date:6/3/2015)... The panel of independent experts has spent ... short-listed for the awards presented tonight at TU-Automotive Detroit ... but the best-of-the-best can now be revealed as: , ... Volvo swept rivals aside by taking the coveted Car ... from our panel of expert judges., Stand out comments ...
(Date:6/3/2015)... NC (PRWEB) June 03, 2015 Researchers ... two biomarkers for mesothelioma and say the tried-and-true marker ... just posted an article on the research. Click ... the University’s National Center for Asbestos Related Diseases say, ... positive results, it is still preferable to fibulin-3 for ...
(Date:6/3/2015)... 03, 2015 For the fourth time in ... ), a full-service advertising agency, has been honored by a ... Commerce. , MCA has been selected as a Semi-Finalist for ... will be honored at a luncheon sponsored by Adcock Financial ... Museum of Art. , “This luncheon will include important information ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Sitting at ... cause discomfort in the back, neck, shoulders and/or wrists. ... musculoskeletal injuries. In addition, recent research links sitting for ... of chronic diseases. Fortunately, three inventors from Oakville, Ontario, ... at a desk. , They have developed a prototype ...
Breaking Medicine News(10 mins):Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2
... Medical Center has just enrolled the first U.S. patient in ... certain kinds of melanoma, a deadly skin cancer that in ... than blocking or killing all rapidly dividing cells, whether malignant ... new class of agents that have been designed to sabotage ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... 30 (HealthDay News) -- Early assessment of rheumatoid arthritis ... the likelihood of disease remission without having to take ... Although DMARDs are considered effective in treating rheumatoid ... been linked to uncommon but serious side effects. ...
... their employer, or through an employed family member,s dependent coverage. ... to a new policy brief from the UCLA Center for ... California Health Interview Survey (CHIS), the brief,s authors found that ... with at least one employed family member or 5.7 ...
... of more than 2 million mammogram screenings performed on nearly ... time show a direct link between reduced hormone therapy and ... invasive breast cancer. The researchers saw such a striking decrease, ... promote breast tumor growth. The declines occurred in ...
... system for Wilson,s disease (WD) provides good diagnostic accuracy ... in children with mild liver disease. In asymptomatic children, ... suggestive of WD, however the penicillamine challenge test (PCT) ... subset. Results of the study appear in the December ...
Cached Medicine News:Health News:International clinical trial tests targeted drug for melanoma 2Health News:Better Outcomes Seen With Early Rheumatoid Arthritis Diagnosis 2Health News:5.7 million Californians lack access to job-based coverage 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 3Health News:Scoring system is 93 percent accurate for diagnosing Wilson's disease in pediatric patients 2
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000CVA test face is used to evaluate both ... levels (high, 25% and 12.5%) of LogMAR acuity ... face as well as the two spatial frequencies ... most widely used for cataract documentation because eye ...
... is used widely for screening refractive surgery ... from 20/10 to 20/100 and one row ... ,The patient can be easily screened in ... contrast sensitivity. If a contrast sensitivity deficit ...
Medicine Products: